A randomised double-blind trial combinding low-dose droperidol and dexamethasone to prevent gastrointestinal adverse interaction induced by hemabate during cesarean delivery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005749

Enrollment

Unknown

Registered

2014-12-27

Start date

2014-12-28

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nausea and vomiting

Interventions

1:droperidol

2:dexamethasone

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Female with a high risk of postpartum hemorrhage need hemabate intramuscularly undergoing cesarean delivery

Exclusion criteria

Exclusion criteria: Patients with the following disease: nause and vomiting history, motion sickness, Asthma,Heart Disease, long Q-T syndrome, Hypertension, Glaucoma, Diabetes and Full stomach maternal. Patients who have nause and vomiting brfore giving hemabate should be also excluded.

Design outcomes

Primary

Measure	Time frame
nausea and vomiting;pulse;BP;	—

Countries

China

Contacts

Public ContactJinping Wang

wjp102@163.com+86 18265545708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026